.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
DELIVER was a large randomized trial of dapagliflozin in patients with heart failure and a mildly reduced or preserved ejection fraction. Dapagliflozin significantly reduced the composite of worsening heart failure or cardiovascular death compared with placebo, extending SGLT2 evidence across the heart-failure spectrum. The benefit was seen irrespective of diabetes status. For internists, the result is important because HFpEF is frequently managed alongside obesity, hypertension, diabetes and chronic kidney disease. Rather than waiting for a single disease-specific therapy, SGLT2 inhibition can now be considered as part of the broader treatment pathway in eligible patients. Monitoring volume status, renal function and tolerability remains necessary, but the key practical point is that glucose lowering is not the primary reason for use in heart failure. DELIVER also supports a phenotype-based approach in which comorbidities are treated together rather than in separate silos.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
DELIVER was a large randomized trial of dapagliflozin in patients with heart failure and a mildly reduced or preserved ejection fraction. Dapagliflozin significantly reduced the composite of worsening heart failure or cardiovascular death compared with placebo, extending SGLT2 evidence across the heart-failure spectrum. The benefit was seen irrespective of diabetes status. For internists, the result is important because HFpEF is frequently managed alongside obesity, hypertension, diabetes and chronic kidney disease. Rather than waiting for a single disease-specific therapy, SGLT2 inhibition can now be considered as part of the broader treatment pathway in eligible patients. Monitoring volume status, renal function and tolerability remains necessary, but the key practical point is that glucose lowering is not the primary reason for use in heart failure. DELIVER also supports a phenotype-based approach in which comorbidities are treated together rather than in separate silos.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
4 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
5 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
4 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
